# Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

> **NCT02638220** · — · COMPLETED · sponsor: **Travere Therapeutics, Inc.** · enrollment: 442 (actual)

## Conditions studied

- Cerebrotendinous Xanthomatosis (CTX)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02638220
- **Lead sponsor:** Travere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2021-02-19
- **Final completion:** 2021-02-19
- **Target enrollment:** 442 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02638220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02638220, "Cerebrotendinous Xanthomatosis (CTX) Prevalence Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02638220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*